Intravesical Instillations of Interferon Gamma in the Prophylaxis of High Risk Superficial Bladder Cancer

Abstract

Intravesically administered IFN gamma has a demonstrable protective role as first line adjuvant treatment in superficial bladder cancer. This role is mainly focused on prevention of recurrences in the short term. Further prospective studies with longer follow up are required, in order to define the exact place of the drug in the urologist's armamentarium.